Belimumab Is Associated with Lower Risk of Progression to LN Compared with Standard of Care in Patients with SLE (LUPUS 2026) - Feb 17, 2026 - Abstract #PO:11:298; 26; Pres time: Mar 6, 2026; 07:30 AM - 07:30 PM; Location: Poster Area; "Index: date of initiation of belimumab or SOC (immunosuppressant [IS, except as LN initial therapy], intravenous glucocorticoids [GCs], or oral GC escalation to >=20 mg/day prednisone-equivalent) between 1 Jan 2017 and 31 Mar 2023...Initiation of LN induction therapy was a proxy for incident LN, defined as earliest use of: subcutaneous belimumab 400 mg once weekly for four doses; voclosporin; cyclophosphamide; high-dose MMF...Use of IS, oral GC, and antimalarial therapies remained imbalanced after weighting and were further adjusted. Patients receiving belimumab had a significantly lower hazard of initiating LN induction therapy versus SOC (hazard ratio [95% CI]: 0.77 [0.62, 0.95]).Abstract PO:11:298 Table 1Select ATT-weighted baseline characteristics Conclusions These findings suggest potential renal protective effects through which belimumab may prevent progression to LN.Funding: GSKOriginal presentation: ACR 2025"
Clinical • Immunology • Inflammatory Arthritis
|
|
Maral Dersarkissian; Yan Chen; Ariel Chao; Shumin Rui; Bronwyn Moore; Karen Worley; Daniel Moldaver; Jeffrey J Ellis; Carmen San Román; Aarat M Patel
|